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Abstract 
The critical role of IgM in controlling pathogen burden has been demonstrated in a 
variety of infection models. In the murine model of Borrelia hermsii infection, IgM is necessary 
and sufficient for the rapid clearance of bacteremia. Convalescent, but not naïve, B1b cells 
generate an IgM-mediated protective response against B. hermsii, but the mechanisms of control 
are unknown. Here we show that neither Fcα/µR, a high-affinity receptor for IgM that mediates 
opsonophagocytosis, nor IgM-dependent complement-activation were required for controlling B. 
hermsii. Bacteria in diffusion chambers were killed when chambers were implanted either into 
convalescent or passively immunized mice. Furthermore, adoptively transferred convalescent 
B1b cells produced IgM that killed bacteria in diffusion chambers. These results demonstrate that 
clearance of B. hermsii does not require opsonophagocytosis and suggest that a mechanism for in 
vivo B1b cell-mediated protection is through the secretion of bactericidal IgM. 
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Introduction 
IgM is the first antibody produced during immune responses, and thus it is important for 
the early control of infection. Natural IgM is generated spontaneously in the absence of antigenic 
stimulation and can contribute to early defense by limiting the initial pathogen burden [1, 2]. 
IgM is also generated in an antigen-specific manner during the early phases of the immune 
response to specific pathogens. Natural IgM as well as antigen-induced IgM has been 
demonstrated in protective immunity to a number of pathogens, such as Streptococcus 
pneumoniae and influenza virus, underscoring the non-redundant roles of natural and antigen-
induced IgM [3, 4].    
 
The vital role of IgM in the rapid control of bacteremia due to infection with relapsing 
fever bacteria is well defined [5, 6]. To study the role of IgM in controlling bacteremia we have 
been utilizing the murine model of infection by Borrelia hermsii, a relapsing fever spirochete 
that causes recurrent episodes of high-level (~108 bacteria/ml blood) bacteremia associated with 
the outgrowth of individual bacterial serotypes [7, 8]. These serotypes are defined by the 
transient expression of antigenically distinct major surface proteins of B. hermsii, the variable 
major proteins (Vmps) [8]. Control of each wave of bacteremia is concurrent with the rapid 
production of specific IgM [9-14]. Mice that are deficient in the secreted form of IgM – but not 
other isotypes – exhibit persistent bacteremia that is identical to that found in mice that lack B 
cell development [14]. In contrast, mice deficient in activation-induced cytidine deaminase – 
which produce only IgM but no other antibody isotypes – control infection indistinguishably 
from wildtype mice [15]. These results demonstrate that IgM is required and sufficient for the 
resolution of B. hermsii bacteremia. 
 4 
  
 Concurrent with the resolution B. hermsii infection there is an expansion of B1b 
lymphocytes (IgMhi, IgDlo, CD23-, CD5-, Mac1+), a minor subset of mature B cells that are 
abundant in the peritoneal cavity [14, 15]. Reconstitution of immunodeficient Rag1-/- mice 
(lacking T and B cells) with expanded B1b cells from convalescent mice confers complete 
immunity, whereas reconstitution with naive B1b cells provides only partial protection, 
demonstrating that convalescent B1b cells have acquired immunological memory [15]. Like 
conventional memory B cells, the reconstituted population persists but does not spontaneously 
secrete B. hermsii-specific antibodies; rather they maintain quiescence. Upon a subsequent 
exposure to antigen, however, memory-like B1b cells rapidly differentiate into antigen-specific 
IgM secreting plasma cells, resulting in a specific antibody response that is faster and to a greater 
magnitude than that of naïve B1b cells [15]. Although the lymphocyte subsets that respond to B. 
hermsii and FhBA, a surface protein of B. hermsii that is recognized by B1b cell-derived IgM 
has been defined [15, 16], it is not clear how such IgM controls this infection in vivo. 
 
The pentameric structure of IgM is known to efficiently induce the classical complement 
pathway (11). Despite this, C3–/– and C5–/– mice control relapsing fever Borrelia infection as 
efficiently as wildtype mice demonstrating that antigen-specific IgM eliminates its targets 
independently of complement [5, 13, 17, 18]. Although IgM is not typically known as an opsonin, 
the discovery of an Fc receptor (FcR) for IgM has suggested a role for IgM in 
opsonophagocytosis. The high-affinity Fcα/µR, which also binds the Fc region of IgA molecules, 
is expressed on macrophages and B cells as well as on non-hematopoietic tissues such as kidney 
and intestine [19-21]. Furthermore, Fcα/µR has been demonstrated to facilitate the phagocytosis 
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of IgM-coated Staphylococcus aureus in vitro, further suggesting its role in clearance of IgM-
coated pathogens [19]. In support of this, specific antibody-coated B. hermsii bacteria are 
engulfed by neutrophils in a complement-independent manner, indicating that antibody-mediated 
opsonophagocytosis is a potential mechanism of clearance of B. hermsii [22]. Nevertheless, it is 
unknown whether Fcα/µR-mediated endocytosis plays a role in facilitating IgM-mediated 
control of pathogens such as B. hermsii in vivo. 
 
In addition to promoting opsonophagocytosis and complement activation, antibodies of 
various isotypes have been shown to exert direct anti-bacterial activities. These antibodies appear 
to exert these effects possibly by catalyzing the production of oxidative molecules [23-25], 
interference with pathogen iron uptake [26, 27], or by directly damaging bacterial membrane [5, 
18]. Among the IgM antibodies that have been described to be bactericidal, CB515 recognizes a 
Vmp expressed by a related relapsing fever Borrelia, lyses bacteria in vitro, and confers a partial 
protection in complement-deficient mice in vivo [18]. The scFv fragments of CB515 retain the 
lytic activity of the parent monoclonal, demonstrating that the bactericidal activity resides in the 
variable region of the antibody [28]. 
 
In this study, we examined the mechanism of B1b cell-derived antibody in control of B. 
hermsii infection in vivo. Here we show that IgM-mediated phagocytosis of B. hermsii is not 
required for control of infection. Using a diffusion chamber model to examine host-pathogen 
interactions, we demonstrate that B1b cells contribute to protective immunity by producing B. 
hermsii-specific antibodies that are directly bactericidal. 
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Materials and Methods 
Mice. The Institutional Animal Care and Use Committee have approved these studies. Mice were 
housed in micro-isolator cages with free access to food and water, and were maintained in a 
specific pathogen-free facility at Thomas Jefferson University. C57BL/6J (B6), Balb/cJ, and 
C57BL/6J-Rag1tm1Mom/J (Rag1–/–) mice were purchased from The Jackson Laboratories (Bar 
Harbor, ME). Fcα/µR-/- mice were described previously [20]. C3-deficient mice on C57BL6 
background (C3-/-) were provided by Robert Eisenberg, University of Pennsylvania. 
 
Infections and cobra venom factor treatment. Mice were infected intravenously (i.v.) via the tail 
vein with 5x104 bacteria of a fully virulent B. hermsii strain DAH-p1 (from the blood of an 
infected mouse), and the bacteremia was monitored by dark-field microscopy. To deplete C3, 
mice were treated i.p. with 30 µg (14.0 units) cobra venom factor (CVF) (Quidel, San Diego, 
CA) one day prior to infection and again on three days post infection as described [29]. This dose 
of CVF is sufficient to maintain C3 levels below 5% of normal levels for four days [30]. 
 
Passive immunizations. To obtain convalescent immune serum, blood was obtained via cardiac 
puncture from wildtype mice that had been infected (>60 days post infection) with B. hermsii. To 
initiate clotting, blood was pooled and incubated at 37°C for 1 hr. After clotting, blood was 
centrifuged at 1000 x g, and serum was collected and filtered through 0.22 µm PES membranes 
(Millipore, Billerica, MA). Passive immunizations were performed by injecting mice with 250 µl 
serum via the tail vein. 
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Enzyme-linked immunosorbent assay (ELISA). IgM levels were measured with ELISA kits 
according to the manufacturer’s instructions (Bethyl Laboratories, Montgomery, TX). B. 
hermsii-specific IgM was determined by coating 96-well plates (ICN Biomedicals Inc., Aurora, 
OH) with in vivo grown B. hermsii DAH (105 wet bacteria/well). Plates were washed and 
blocked with 2% BSA in PBS pH 7.2 for 2 hr at room temperature. Blood samples of immunized 
mice were diluted 1:250 and samples were centrifuged (16000 x g for 10 min.) and supernatant 
was used. Bound IgM was measured using HRP-conjugated goat anti-mouse IgM. Specific 
antibody levels were interpreted as ng/µl equivalents using IgM standards. 
 
Diffusion chambers. Mixed cellulose ester (MCE) membranes (0.05 µm pore size; Millipore) 
were adhered to lucite diffusion chamber rings (weight - 0.4 g; diameter - 14 mm; Width - 5 mm; 
Millipore) using cement as described previously [31]. Chambers were loaded with 200 µl of in 
vivo-adapted B. hermsii strain DAH in BSK-H (Sigma-Aldrich, St. Louis, MO) supplemented 
with 6% rabbit serum (Sigma-Aldrich) at 6.67 x 106 bacteria/ml (1.33 x 106 bacteria per 
chamber), and chambers were sealed. Mice were anesthetized with 3% isoflurane, and using 
aseptic technique, chambers were implanted in a subcutaneous pocket formed by making an 
incision of approximately 1.5 cm in the dorsal-anterior skin of each mouse. Chambers were 
removed after 24 hours, and contents were collected. Bacterial density in the chamber was 
measured by dark-field microscopy. Chamber contents were stored at -20°C until analyzed. In 
some experiments, mice were passively immunized with a) 250 µl convalescent immune serum 
or b) treated with 14.0 units CVF one day prior to implantation as described above. 
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B1b cell reconstitution. Rag1–/– mice were reconstituted with 105 MACS-purified B1b cells from 
convalescent (i.e., resolved B. hermsii DAH infection) mice as described [15]. Because Rag1–/– 
mice reconstituted with convalescent B1b cells do not generate a specific IgM response without 
bacterial stimulation, they were infected i.v. with 5 x 104 bacteria of the B. hermsii DAH ten 
days after adoptive transfer of B1b cells. 
 
Statistical analysis. Statistics were performed using the Prism 5 software program (GraphPad 
Software, Inc., La Jolla, CA). To analyze statistical significance, two-tailed unpaired Student’s t-
test or two-way ANOVA were used as necessary.  
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Results 
Clearance of B. hermsii does not require Fcα/µR-mediated opsonophagocytosis. C3-/- and 
C5-/- mice control relapsing fever infection, suggesting that other mechanisms such as 
opsonophagocytosis play a role in IgM-mediated control of B. hermsii [13]. Indeed, antibody has 
been shown to enhance opsonophagocytosis of B. hermsii by neutrophils in vitro [22]. Recently 
Fcα/µR, a specific receptor for IgM, has been shown to mediate opsonophagocytosis of IgM-
coated S. aureus [19]. Since antibodies in particular IgM is critical for the protection against B. 
hermsii, to examine whether Fcα/µR plays a role in IgM-mediated opsonophagocytosis, we 
infected mice deficient in Fcα/µR. The magnitude and duration of B. hermsii bacteremia during 
the first episode in these mice were comparable to that of wildtype (Figure 1A). Moreover, 
passive immunization confers protection to Fcα/µR-/- mice indicating that immune serum control 
B. hermsii in an Fcα/µR-independent manner (Figure 1B).  Consistent with the critical role for 
IgM in control of this bacterium, Fcα/µR-/- mice rapidly generated a B. hermsii-specific IgM 
response to a similar extent as in wildtype mice (Figure 1C). Although infection with B. hermsii 
does eventually elicit an IgG response, this does not occur until after the first wave of bacteremia 
is cleared. Thus, the IgM-mediated clearance of the first wave does not require Fcα/µR-mediated 
opsonophagocytosis.  
 
Control of B. hermsii in the absence of Fcα/µR-mediated opsonophagocytosis is 
independent of C3. It is known that control of relapsing fever bacteremia occurs independently 
of the complement system, as bacterial clearance occurs in the absence of C3 and C5 [13]. These 
results suggest that complement either does not contribute to clearance or that other mechanisms 
such as opsonophagocytosis operate in a redundant fashion. To examine whether complement-
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mediated lysis or complement-mediated opsonophagocytosis was plays a critical function in the 
absence of Fcα/µR-mediated opsonophagocytosis, we depleted C3 in wildtype and Fcα/µR-/- 
mice with cobra venom factor (CVF). One day prior to infection, mice were treated with 30 µg 
of CVF (14.0 units) i.p., which is sufficient to deplete C3 to less than 5% of normal levels for 
four days [29, 30]. At three days post-infection, mice were treated with the same dose to 
maintain C3 depletion. Despite a deficiency in both Fcα/µR and C3, the magnitude of the 
bacteremia was similar in CVF-treated and -untreated wildtype and Fcα/µR-/- mice (Figure 2). 
These results indicate that the effector mechanism of B. hermsii-specific IgM is neither C3- nor 
Fcα/µR-dependent. 
 
Antibody-mediated control of B. hermsii does not require phagocytic cell contact. Since 
phagocytosis can be promoted by a variety of other mechanisms, we tested whether IgM-
mediated in vivo control of B. hermsii in vivo requires cell contact. To test this, we adapted a 
diffusion chamber system originally devised to model the host-pathogen interaction during 
parasite infections [31]. The permeability of these chambers (0.05 µm) was large enough to 
allow free diffusion of IgM (300 Å) while restricting both the escape of B. hermsii (~0.25 x ~5.0 
µm) and the entrance of host cells. Each chamber contained 1.33 x 106 in vivo-adapted B. hermsii 
spirochetes in bacterial growth medium. A schematic for the diffusion chamber model is 
represented in Figure 3A. After 24 hours in naïve mice, the number of bacteria in each chamber 
was approximately threefold higher than the initial number in each chamber. In contrast, the 
number of bacteria in chambers implanted in convalescent mice was nearly undetectable (Figure 
3B). 
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 The numbers of B. hermsii were also reduced significantly in the chambers implanted in 
passively immunized mice (Figure 3B). Interestingly, the degree of bacterial killing in these mice 
was to a lesser extent than what was observed in the chambers implanted in convalescent mice, 
suggesting that the amount of specific IgM present in the chamber had a direct effect on bacterial 
killing inside the chambers. Therefore, we examined specific IgM levels in the chambers taken 
from naïve mice, convalescent mice, and naïve mice that were given convalescent immune 
serum. As expected, we found that specific IgM had entered the chambers implanted in 
convalescent mice and passively immunized naïve mice. Furthermore, increasing amounts of 
specific IgM in each chamber inversely correlated with bacterial viability (Figure 3C). These 
results demonstrate that lysis of B. hermsii in diffusion chambers is IgM-dependent and does not 
require cell contact. 
 
Killing of B. hermsii in diffusion chambers is C3-independent. As described above, IgM 
controls B. hermsii independent of C3 or Fcα/µR-mediated opsonophagocytosis. To test whether 
cell contact-independent killing of B. hermsii in diffusion chambers is also complement 
independent, we depleted C3 in naïve and convalescent wildtype mice with CVF one day prior to 
implantation of diffusion chambers. As expected, bacterial growth was unhindered in naïve mice 
regardless of whether complement was depleted (Figure 4). In contrast, there were no bacteria 
remaining in chambers removed from convalescent mice irrespective of the presence of C3 
(Figure 4A).  
 
To independently confirm that IgM is bactericidal in vivo independent of the complement 
system, we used mice deficient in both the alternative and classical complement pathways due to 
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a targeted deletion in C3. Diffusion chambers containing 1.33 x 106 B. hermsii bacteria were 
implanted into convalescent wildtype and C3-/- mice. In agreement with the above results, 
bacteria in diffusion chambers were killed in both wildtype and C3-/- mice (Figure 4B). These 
results demonstrate that C3 is not required for antibody-mediated lysis of B. hermsii in the 
diffusion chambers. 
 
B1b cell-derived antibodies are sufficient to kill B. hermsii in diffusion chambers. Clearance 
of B. hermsii is T cell-independent, and expansion of the peritoneal B1b cell pool is observed 
concurrent with the resolution of infection [15]. B1b cells exhibit TI memory, and reinfection 
with B. hermsii results in the rapid generation of specific IgM that is capable of controlling 
disease in the absence of any other adaptive immune cells [15]. To determine whether B1b-
derived IgM is capable of clearing B. hermsii independently of opsonophagocytosis, we tested 
whether IgM generated by adoptively transferred convalescent B1b cells was able to kill B. 
hermsii in diffusion chambers.  
 
Rag1-/- mice reconstituted with purified convalescent B1b cells and primed with B. 
hermsii generated a B. hermsii-specific IgM response (Figure 5A). To measure cell-independent 
killing by B1b-derived IgM, we implanted diffusion chambers containing 1.33 x 106 spirochetes 
in reconstituted Rag1-/- mice at ten days post-infection. As expected, B. hermsii bacteria in 
diffusion chambers proliferated vigorously when implanted in unreconstituted Rag1-/- recipients. 
On the other hand, we observed a significant decrease in the number of live bacteria in chambers 
implanted in mice reconstituted with convalescent B1b cells (Figure 5B). These results 
demonstrate that IgM generated by B1b cells is directly bactericidal in vivo. 
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Discussion 
IgM is the dominant isotype secreted upon antigen encounter and plays a critical role in 
immunity to a number of infections [2]. The production of specific IgM is required and sufficient 
to control bacteremia during relapsing fever infection [14, 15]. We have previously shown that 
B1b cells generate B. hermsii-specific IgM that is capable of controlling B. hermsii bacteremia. 
Here we show that the IgM-mediated control of B. hermsii bacteremia is independent of Fcα/µR 
and C3 and does not require cell contact. Our data indicate that the mechanism of B1b-mediated 
control of B. hermsii is through the secretion of bactericidal antibodies. 
 
Although antibodies tend to exert their protective function through the activation of the 
complement cascade or via Fc receptor engagement, some exert direct damage to pathogens in a 
variety of ways. For example, a Pseudomonas aeruginosa LPS-specific IgG alters cell wall 
permeability, formation of cell wall vesicular structures, elongation, and inhibition of cell 
division [32]. The bactericidal IgG CB2, specific for OspB of Borrelia burgdorferi, induces the 
formation of 2.8 - 4.4 nm pores in the outer membrane of the bacterium [33]. Paradoxically, this 
antibody does not induce lysis of OspB-expressing E. coli, indicating that IgG-induced lysis is 
dependent on the cell membrane structure of B. burgdorferi or the expression of another B. 
burgdorferi protein. In fact, the lytic activity of CB2 depends on cholesterol domains in the outer 
membrane of B. burgdorferi, suggesting that CB2 alters the fluid structure of the bacterial outer 
membrane [34]. In addition, B. burgdorferi has been shown to harbor a prophage holin or holin-
like system containing the genes blyA and blyB on the conserved circular plasmid cp32 [35]. 
Transformation of E. coli with blyA induces cell membrane damage in the host cell that is 
dependent on a host cytolysin ClyA acting in trans, demonstrating that the gene product of blyA 
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is functional [36]. Remarkably, treatment of B. burdgorferi spirochetes with sublethal quantities 
of CB2 induced the expression of cp32 gene products BlyA and BlyB, suggesting that the 
bactericidal activity of CB2 may be dependent on the induced expression of bacteriophage gene 
products [37]. Finally, as described above, bactericidal activity of the V region of an IgM 
specific for a Vmp expressed by a related relapsing fever Borrelia results in direct lysis of the 
bacterial outer membrane [18]. In spite of this observation, the precise biochemical mechanism 
of this lysis is unknown. Due to the homology between B. burdgorferi, Spanish relapsing fever 
and B. hermsii, it is tempting to speculate that bactericidal B1b-derived IgM lyses B. hermsii in 
the same mechanism as described by Benach and colleagues. More extensive studies will be 
required to determine the exact mechanism by which bactericidal IgM kills its targets. 
 
B1b cells have been shown to play a role in controlling a number of bacterial pathogens 
including B. hermsii, Streptococcus pneumoniae and non-typhoidal Salmonella [4, 15, 38]}. In 
the absence of all other B cell types, convalescent B1b cells are sufficient to provide protection 
to infection of immunodeficient mice with B. hermsii. We have shown that FhBA, an outer 
surface protein of B. hermsii is specifically recognized by the IgM secreted by convalescent B1b 
cells [16]. The previously described anti-Borrelia antibodies recognize major surface bacterial 
proteins such as OspB and Vmps rather than FhBA. Despite having shown that B1b cells secrete 
B. hermsii-specific IgM that is capable of leading to direct bacterial lysis, the biochemical basis 
for this lysis of B. hermsii is unknown. The generation of B1b-derived monoclonal antibodies to 
FhBA of B. hermsii the characterization of such antibodies would provide a better insight on 
how B1b cell-derived antibodies exert their antibacterial activity in the complete absence of a 
cell-contact. 
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Figure Legends 
Figure 1. Fcα/µR-mediated opsonophagocytosis is not required for clearance of B. hermsii.  
(A). Balb/cJ or Fcα/µR-/- mice were infected i.p. with B. hermsii strain DAH, and bacteremia 
was monitored by dark-field microscopy. Each plot represents an individual mouse. Dotted lines 
represent limit of detection. (B).. One day prior to infection with strain DAH, serum from 
convalescent (80 days post-infection) wildtype mice was passively transferred either into Balb/cJ 
or Fcα/µR-/- mice. Bacteremia was monitored by dark-field microscopy. Dotted lines represent 
the limit of detection. (C). B. hermsii-specific IgM was measured by ELISA. Data points 
represent mean ± SD. Kinetics of anti-B. hermsii IgM responses were not statistically significant 
between wildtype and Fcα/µR-/- mice.  
 
Figure 2. Fcα/µR- and C3-mediated opsonophagocytosis are not required for clearance of 
B. hermsii. (A) Balb/cJ or (B) Fcα/µR-/- mice were treated without or with 14.0 units of cobra 
venom factor (CVF) to deplete complement component C3 on the days indicated (arrows). Mice 
were infected with B. hermsii, and bacteremia was monitored by dark-field microscopy. Each 
plot represents an individual mouse. Dotted lines represent limit of detection. 
 
Figure 3. Antibody-mediated lysis in diffusion chambers. (A) Diffusion chamber model. B. 
hermsii (size: ~0.25 µm x ~5.0 µm) and eukaryotic cells are unable to pass through the 0.05 µm 
pores size membrane of the diffusion chambers. IgM (300 Å) passively diffuses through the 
chamber membrane. (B) Chambers containing 1.33 x 106 B. hermsii were implanted into various 
groups of B6 mice (n= 4-7 per group) as shown in A. Chambers were removed after 24 hours and 
live bacteria were enumerated by dark-field microscopy. Data represent mean ± SD. Dotted line 
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represents starting number of bacteria in each chamber. Data were analyzed by two-tailed 
unpaired Student’s t test, with significance reached at p < 0.05. (C) B. hermsii-specific IgM in 
diffusion chambers was measured by ELISA, and specific IgM values were matched with 
chamber bacterial density. Non-linear regression analysis measuring the effect of specific IgM 
concentration on bacterial death was performed. 
 
Figure 4. Lysis of B. hermsii in diffusion chambers is C3-independent. (A) Cobra venom 
factor (CVF, 14.0 units) was given to naïve (n=4) or convalescent  (n=5) B6 mice one day prior 
to implantation of diffusion chambers containing B. hermsii. Control groups of naïve (n=3) or 
convalescent  (n=3) mice were given DPBS. (B) Chambers containing 1.33 x 106 B. hermsii were 
implanted into naïve B6 mice (n=4), convalescent B6 mice (n=4), or convalescent C3-/- mice 
(n=3). For A and B, chambers were removed from mice after 24 hours, and bacteria were counted 
by dark-field microscopy. Mean numbers of bacteria ± SD are shown. (N.D. – not detectable). 
Dotted line indicates starting number of bacteria in each chamber. Data were analyzed by two-
tailed unpaired Student’s t test, with significance reached at p < 0.05. 
 
Figure 5. B1b cell-derived IgM is sufficient to kill B. hermsii in diffusion chambers. Rag1-/- 
mice were reconstituted without or with B1b cells (105 cells per mouse) from convalescent B6 
mice. After 10 days, B1b cell reconstituted mice were infected with B. hermsii in order to 
stimulate IgM production. (A) B. hermsii-specific IgM in non-reconstituted (n=4) or B1b-
reconstituted mice (n=4) was determined by ELISA. Means ± SD are shown. Data were analyzed 
by two-way ANOVA, with significance reached at p < 0.05. (B) On day 10 post-infection, 
chambers containing B. hermsii were implanted into mice from each group. Twenty-four hours 
 18 
later chambers were removed, and live bacteria were counted by dark-field microscopy. Dotted 
line represents the starting number of B. hermsii in each chamber. Data were analyzed by two-
tailed unpaired Student’s t test, with significance reached at p < 0.05.  
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